Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2017 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights

Sunesis to Host Conference Call Today at 11:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial...
March 02, 2017 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis to Host Conference Call on March 9th to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 9, 2017 at 11:00...
March 01, 2017 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at...
February 06, 2017 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at...
January 23, 2017 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Announces Clinical and Regulatory Updates to SNS-062 and Vosaroxin Programs

FDA Review of Investigational New Drug Application for SNS-062 Complete; Phase 1B/2 Study in Patients with Advanced B-Cell Malignancies to Begin Dosing in the First Half of 2017 Vosaroxin Day 180...
December 05, 2016 17:45 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Announces Presentation of Updated Results from the VALOR Trial Examining Overall Survival in Patients Age 60 Years and Older with Relapsed/Refractory AML at the ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from the VALOR trial examining overall...
December 05, 2016 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Announces Presentation of Results from Completed Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062 at ASH Annual Meeting

Program On Track to Begin Dosing in Phase 1B/2 Study of Patients with B-Cell Malignancies in the First Half of 2017 SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Sunesis...
November 03, 2016 09:25 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Announces Presentations at ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced an oral and a poster presentation at the 58th American Society of...
November 03, 2016 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the third quarter ended September 30, 2016. Loss...
October 27, 2016 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis to Host Conference Call on November 3rd to Discuss Third Quarter 2016 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it will host a conference call on Thursday, November 3, 2016 at...